Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

TSPYL5 suppresses p53 levels and function by physical interaction with USP7


We have previously reported a gene expression signature that is a powerful predictor of poor clinical outcome in breast cancer1. Among the seventy genes in this expression profile is a gene of unknown function: TSPYL5 (TSPY-like 5, also known as KIAA1750). TSPYL5 is located within a small region at chromosome 8q22 that is frequently amplified in breast cancer, which suggests that TSPYL5 has a causal role in breast oncogenesis2,3. Here, we report that high TSPYL5 expression is an independent marker of poor outcome in breast cancer. Mass spectrometric analysis revealed that TSPYL5 interacts with ubiquitin-specific protease 7 (USP7; also known as herpesvirus-associated ubiquitin-specific protease; HAUSP). USP7 is the deubiquitylase for the p53 tumour suppressor4 and TSPYL5 reduces the activity of USP7 towards p53, resulting in increased p53 ubiquitylation. We demonstrate that TSPYL5 reduces p53 protein levels and inhibits activation of p53-target genes. Furthermore, expression of TSPYL5 overrides p53-dependent proliferation arrest and oncogene-induced senescence, and contributes to oncogenic transformation in multiple cell-based assays. Our data identify TSPYL5 as a suppressor of p53 function through its interaction with USP7.

Your institute does not have access to this article

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1: TSPYL5 is a poor-prognosis marker in breast cancer and binds to USP7.
Figure 2: TSPYL5 increases p53 ubiquitylation and suppresses p53 protein levels.
Figure 3: TSPYL5 inhibits p53 transactivation and target gene transcription.
Figure 4: TSPYL5 inhibits oncogene-induced senescence and allows transformation.


  1. van 't Veer, L. J. et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530–536 (2002).

    CAS  Article  Google Scholar 

  2. Li, Y. et al. Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer. Nat. Med. 16, 214–218 (2010).

    Article  Google Scholar 

  3. Hu, G. et al. MTDH activation by 8q22 genomic gain promotes chemoresistance and metastasis of poor-prognosis breast cancer. Cancer Cell 15, 9–20 (2009).

    CAS  Article  Google Scholar 

  4. Li, M. et al. Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization. Nature 416, 648–653 (2002).

    CAS  Article  Google Scholar 

  5. Vousden, K. H. & Lane, D. P. p53 in health and disease. Nat. Rev. Mol. Cell Biol. 8, 275–283 (2007).

    CAS  Article  Google Scholar 

  6. Vogelstein, B., Lane, D. & Levine, A. J. Surfing the p53 network. Nature 408, 307–310 (2000).

    CAS  Article  Google Scholar 

  7. Riley, T., Sontag, E., Chen, P. & Levine, A. Transcriptional control of human p53-regulated genes. Nat. Rev. Mol. Cell Biol. 9, 402–412 (2008).

    CAS  Article  Google Scholar 

  8. Brooks, C. L. & Gu, W. p53 ubiquitination: Mdm2 and beyond. Mol. Cell 21, 307–315 (2006).

    CAS  Article  Google Scholar 

  9. van de Vijver, M. J. et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347, 1999–2009 (2002).

    CAS  Article  Google Scholar 

  10. Paik, S. et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351, 2817–2826 (2004).

    CAS  Article  Google Scholar 

  11. Ma, X. J. et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 5, 607–616 (2004).

    CAS  Article  Google Scholar 

  12. Sorlie, T. et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA 98, 10869–10874 (2001).

    CAS  Article  Google Scholar 

  13. Fan, C. et al. Concordance among gene-expression-based predictors for breast cancer. N. Engl. J. Med. 355, 560–569 (2006).

    CAS  Article  Google Scholar 

  14. Hu, M. et al. Crystal structure of a UBP-family deubiquitinating enzyme in isolation and in complex with ubiquitin aldehyde. Cell 111, 1041–1054 (2002).

    CAS  Article  Google Scholar 

  15. Li, M., Brooks, C. L., Kon, N. & Gu, W. A dynamic role of HAUSP in the p53-Mdm2 pathway. Mol. Cell 13, 879–886 (2004).

    CAS  Article  Google Scholar 

  16. Cummins, J. M. et al. Tumour suppression: disruption of HAUSP gene stabilizes p53. Nature 428, doi:10.1038/nature02501 (2004).

  17. Vassilev, L. T. et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844–848 (2004).

    CAS  Article  Google Scholar 

  18. Scheffner, M., Huibregtse, J. M., Vierstra, R. D. & Howley, P. M. The HPV-16 E6 and E6–AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75, 495–505 (1993).

    CAS  Article  Google Scholar 

  19. Brummelkamp, T. R. et al. TBX-3, the gene mutated in Ulnar-Mammary Syndrome, is a negative regulator of p19ARF and inhibits senescence. J. Biol. Chem. 277, 6567–6572 (2002).

    CAS  Article  Google Scholar 

  20. Sherr, C. J. Divorcing ARF and p53: an unsettled case. Nat. Rev. Cancer 6, 663–673 (2006).

    CAS  Article  Google Scholar 

  21. Flatt, P. M. et al. p53-dependent expression of PIG3 during proliferation, genotoxic stress, and reversible growth arrest. Cancer Lett. 156, 63–72 (2000).

    CAS  Article  Google Scholar 

  22. Voorhoeve, P. M. et al. A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Cell 124, 1169–1181 (2006).

    CAS  Article  Google Scholar 

  23. Kuilman, T. et al. Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell 133, 1019–1031 (2008).

    CAS  Article  Google Scholar 

  24. Borgdorff, V. et al. Multiple microRNAs rescue from Ras-induced senescence by inhibiting p21(Waf1/Cip1). Oncogene 29, 2262–2271 (2010).

    CAS  Article  Google Scholar 

  25. Voorhoeve, P. M. & Agami, R. The tumor-suppressive functions of the human INK4A locus. Cancer Cell 4, 311–319 (2003).

    CAS  Article  Google Scholar 

  26. Holowaty, M. N., Sheng, Y., Nguyen, T., Arrowsmith, C. & Frappier, L. Protein interaction domains of the ubiquitin-specific protease, USP7/HAUSP. J. Biol. Chem. 278, 47753–47761 (2003).

    CAS  Article  Google Scholar 

  27. Saridakis, V. et al. Structure of the p53 binding domain of HAUSP/USP7 bound to Epstein-Barr nuclear antigen 1 implications for EBV-mediated immortalization. Mol. Cell 18, 25–36 (2005).

    CAS  Article  Google Scholar 

  28. Pharoah, P. D., Day, N. E. & Caldas, C. Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis. Br. J. Cancer 80, 1968–1973 (1999).

    CAS  Article  Google Scholar 

  29. Miller, L. D. et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects and patient survival. Proc. Natl Acad. Sci. USA 102, 13550–13555 (2005).

    CAS  Article  Google Scholar 

  30. Kon, N. et al. Inactivation of HAUSP in vivo modulates p53 function. Oncogene 29, 1270–1279 (2010).

    CAS  Article  Google Scholar 

  31. Gentleman, R. C. et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 5, R80 (2004).

    Article  Google Scholar 

  32. de Boer, E. et al. Efficient biotinylation and single-step purification of tagged transcription factors in mammalian cells and transgenic mice. Proc. Natl Acad. Sci. USA 100, 7480–7485 (2003).

    CAS  Article  Google Scholar 

Download references


We thank C. Bishop and D. Beach for the gift of HMEC cells with inducible RASV12 and members of the Bernards and Pandolfi laboratories for discussions and critical reading of the manuscript. This work was supported by grants from the Dutch Cancer Society and the Netherlands Genomics Initiative to R.B., by grants from the Netherlands Proteomics Centre and the Netherlands Genomics Initiative to J.L.B. and by NIH grants to P.P.P.

Author information

Authors and Affiliations



The experiments were conceived and designed by M.T.E., P.P.P. and R.B. Experiments were performed by M.T.E. Mass spectrometry was performed by L.A.T.M. and supervised by J.L.B. Statistical analysis of gene expression in breast cancer was performed by O.K. The paper was written by M.T.E., P.P.P. and R.B.

Corresponding author

Correspondence to René Bernards.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary Information

Supplementary Information (PDF 855 kb)

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Epping, M., Meijer, L., Krijgsman, O. et al. TSPYL5 suppresses p53 levels and function by physical interaction with USP7. Nat Cell Biol 13, 102–108 (2011).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:

Further reading


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing